Children's Oncology Group

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

Phase 3

Active, not recruiting

Conditions: Alveolar Rhabdomyosarcoma
Botryoid-Type Embryonal Rhabdomyosarcoma
Embryonal Rhabdomyosarcoma
Metastatic Embryonal Rhabdomyosarcoma
Metastatic Rhabdomyosarcoma
Solid Alveolar Rhabdomyosarcoma
Spindle Cell Rhabdomyosarcoma
Spindle Cell/Sclerosing Rhabdomyosarcoma

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Bone Scan
Procedure: Computed Tomography
Drug: Cyclophosphamide
Biological: Dactinomycin
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
Radiation: Radiation Therapy
Drug: Vincristine Sulfate
Drug: Vinorelbine Tartrate
Procedure: X-Ray Imaging

First Posted Date: 2021-08-06

Last Posted Date: 2025-06-10

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 118

Registration Number: NCT04994132

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
USA Health Strada Patient Care Center, Mobile, Alabama, United States
🇺🇸
Providence Alaska Medical Center, Anchorage, Alaska, United States

and more 248 locations

A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor

Phase 3

Active, not recruiting

Conditions: Central Nervous System Carcinoma

Interventions: Procedure: Biospecimen Collection
Procedure: Cognitive Assessment
Procedure: Magnetic Resonance Imaging
Drug: Memantine Hydrochloride
Drug: Placebo Administration
Other: Questionnaire Administration

First Posted Date: 2021-06-25

Last Posted Date: 2025-06-15

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 192

Registration Number: NCT04939597

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Providence Alaska Medical Center, Anchorage, Alaska, United States
🇺🇸
Banner Children's at Desert, Mesa, Arizona, United States

and more 135 locations

Financial Distress During Treatment for Pediatric Acute Lymphoblastic Leukemia in the United States

Active, not recruiting

Conditions: Acute Lymphoblastic Leukemia

Interventions: Other: Electronic Health Record Review
Other: Interview
Other: Survey Administration

First Posted Date: 2021-06-16

Last Posted Date: 2025-06-11

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 100

Registration Number: NCT04928599

Locations: 🇺🇸
Kaiser Permanente-Oakland, Oakland, California, United States
🇺🇸
Alfred I duPont Hospital for Children, Wilmington, Delaware, United States
🇺🇸
Broward Health Medical Center, Fort Lauderdale, Florida, United States

and more 37 locations

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Phase 1

Recruiting

Conditions: Diffuse Midline Glioma, H3 K27M-Mutant
Recurrent Diffuse Intrinsic Pontine Glioma
Metastatic Malignant Neoplasm in the Central Nervous System
Recurrent Osteosarcoma
Refractory Malignant Solid Neoplasm
Refractory Primary Malignant Central Nervous System Neoplasm
Recurrent Lymphoma
Recurrent Primary Malignant Central Nervous System Neoplasm
Refractory Osteosarcoma
Refractory Lymphoma

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspirate
Procedure: Bone Marrow Biopsy
Procedure: Echocardiography
Drug: FACT Complex-targeting Curaxin CBL0137

First Posted Date: 2021-05-04

Last Posted Date: 2025-02-13

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 95

Registration Number: NCT04870944

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Children's Hospital of Orange County, Orange, California, United States

and more 29 locations

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Phase 1

Recruiting

Conditions: Neuroblastoma
Refractory Desmoid Fibromatosis
Wilms Tumor
Colorectal Carcinoma
Recurrent Hepatoblastoma
Recurrent Malignant Solid Neoplasm
Recurrent Osteosarcoma
Refractory Hepatocellular Carcinoma
Refractory Osteosarcoma
Solid Pseudopapillary Neoplasm of the Pancreas

Interventions: Procedure: Biospecimen Collection
Procedure: Dual X-ray Absorptiometry
Drug: Tegavivint
Procedure: X-Ray Imaging

First Posted Date: 2021-04-20

Last Posted Date: 2024-10-26

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 147

Registration Number: NCT04851119

Locations: 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States

and more 18 locations

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

Phase 2

Recruiting

Conditions: Embryonal Carcinoma
Malignant Teratoma
Choriocarcinoma
Mixed Germ Cell Tumor
Pineal Region Germ Cell Tumor
Central Nervous System Nongerminomatous Germ Cell Tumor
Immature Teratoma
Suprasellar Germ Cell Tumor
Pineal Region Immature Teratoma
Pineal Region Yolk Sac Tumor

Interventions: Procedure: Biospecimen Collection
Drug: Carboplatin
Drug: Etoposide
Biological: Filgrastim
Drug: Ifosfamide
Procedure: Magnetic Resonance Imaging
Drug: Mesna
Biological: Pegfilgrastim
Procedure: Peripheral Blood Stem Cell Transplantation
Other: Questionnaire Administration
Radiation: Radiation Therapy
Procedure: Second-Look Surgery
Drug: Thiotepa

First Posted Date: 2020-12-24

Last Posted Date: 2025-06-11

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 160

Registration Number: NCT04684368

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Providence Alaska Medical Center, Anchorage, Alaska, United States
🇺🇸
Banner Children's at Desert, Mesa, Arizona, United States

and more 157 locations

Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)

Phase 2

Active, not recruiting

Conditions: Ganglioneuroblastoma, Nodular
Neuroblastoma

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Biological: Dinutuximab
Procedure: FDG-Positron Emission Tomography
Radiation: Iobenguane I-123
Drug: Irinotecan
Drug: Isotretinoin
Procedure: Magnetic Resonance Imaging
Procedure: Multigated Acquisition Scan
Biological: Sargramostim
Drug: Temozolomide

First Posted Date: 2020-05-12

Last Posted Date: 2024-10-22

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 41

Registration Number: NCT04385277

Locations: 🇺🇸
Banner Children's at Desert, Mesa, Arizona, United States
🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸
Kaiser Permanente Downey Medical Center, Downey, California, United States

and more 74 locations

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

Phase 2

Recruiting

Conditions: Anaplastic Kidney Wilms Tumor
Stage III Kidney Wilms Tumor
Recurrent Kidney Wilms Tumor
Stage II Kidney Wilms Tumor
Stage IV Kidney Wilms Tumor

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Bone Scan
Drug: Carboplatin
Procedure: Computed Tomography
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Etoposide
Drug: Ifosfamide
Drug: Irinotecan
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
Radiation: Radiation Therapy
Procedure: Surgical Procedure
Procedure: Transabdominal Ultrasound
Drug: Topotecan
Drug: Vincristine
Procedure: X-Ray Imaging

First Posted Date: 2020-03-26

Last Posted Date: 2025-06-10

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 256

Registration Number: NCT04322318

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
USA Health Strada Patient Care Center, Mobile, Alabama, United States
🇺🇸
Providence Alaska Medical Center, Anchorage, Alaska, United States

and more 198 locations

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Phase 3

Recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Asparaginase Erwinia chrysanthemi
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Drug: Cytarabine
Drug: Daunorubicin Hydrochloride
Drug: Dexrazoxane Hydrochloride
Drug: Etoposide
Other: Fludeoxyglucose F-18
Drug: Liposome-encapsulated Daunorubicin-Cytarabine
Drug: Gemtuzumab Ozogamicin
Procedure: Magnetic Resonance Imaging
Drug: Gilteritinib Fumarate
Drug: Methotrexate
Procedure: Positron Emission Tomography
Drug: Mitoxantrone Hydrochloride
Other: Questionnaire Administration
Drug: Therapeutic Hydrocortisone

First Posted Date: 2020-03-03

Last Posted Date: 2025-06-11

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 1186

Registration Number: NCT04293562

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
USA Health Strada Patient Care Center, Mobile, Alabama, United States
🇺🇸
Banner Children's at Desert, Mesa, Arizona, United States

and more 201 locations

Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia

Phase 1

Active, not recruiting

Conditions: Accelerated Phase Chronic Myelogenous Leukemia
Philadelphia Chromosome Positive CML
Blastic Phase Chronic Myelogenous Leukemia
Chronic Phase Chronic Myelogenous Leukemia

Interventions: Drug: Bosutinib

First Posted Date: 2020-02-06

Last Posted Date: 2025-06-19

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 60

Registration Number: NCT04258943

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Phoenix Childrens Hospital, Phoenix, Arizona, United States
🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States

and more 56 locations

AI-Powered Research

Premium Access

Children's Oncology Group

A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor

Financial Distress During Treatment for Pediatric Acute Lymphoblastic Leukemia in the United States

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia